Efficacy of HMJ-38, a new quinazolinone analogue, against the gemcitabine-resistant MIA-PaCa-2 pancreatic cancer cells
Mann-Jen Hour, Fuu-Jen Tsai, I-Lu Lai, Je-Wei Tsao, Jo-Hua Chiang, Yu-Jen Chiu, Hsing-Fang Lu, Yu-Ning Juan, Jai-Sing Yang, Shih-Chang Tsai · 2023
Read Efficacy of HMJ-38, a new quinazolinone analogue, against the gemcitabine-resistant MIA-PaCa-2 pancreatic cancer cells by Mann-Jen Hour, Fuu-Jen Tsai, I-Lu Lai, Je-Wei Tsao, Jo-Hua Chiang, Yu-Jen Chiu, Hsing-Fang Lu, Yu-Ning Juan, Jai-Sing Yang, Shih-Chang Tsai (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10962539.txt.
Description
Mann-Jen Hour and co-authors published a 2023 study on a new compound against pancreatic cancer that resists the standard drug. The standard drug, gemcitabine, often fails as tumors learn to withstand it. The team first bred a line of pancreatic cancer cells that shrug off the drug. They then tested a new molecule, HMJ-38, on those hardened cells.
The resistant cells ignored doses of the standard drug that would kill normal cancer cells. The new compound slowed their growth and pushed them toward two forms of death: a self-eating process and programmed cell death. Blocking the self-eating process made the compound even deadlier. Blocking cell death rescued the cells, confirming both paths matter. Computer screening named a growth receptor as a main target, and lab tests confirmed it blocks that receptor's activity.
Catalog record
| CREATOR | Mann-Jen Hour, Fuu-Jen Tsai, I-Lu Lai, Je-Wei Tsao, Jo-Hua Chiang, Yu-Jen Chiu, Hsing-Fang Lu, Yu-Ning Juan, Jai-Sing Yang, Shih-Chang Tsai |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 27 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |